Maria Grazia Spillantini

List of Publications by Year
in descending order

96 papers	23,431 citations	34493 54 h-index	51423 90 g-index
98 all docs	98 docs citations	98 times ranked	22170 citing authors

#	Article	IF	Citations
1	Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype. Molecular Therapy, 2022, 30, 1465-1483.	3.7	9
2	Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. EBioMedicine, 2022, 80, 104021.	2.7	26
3	CSPÎ± reduces aggregates and rescues striatal dopamine release in Î±-synuclein transgenic mice. Brain, 2021, 144, 1661-1669.	3.7	14
4	Super-resolution imaging reveals Î±-synuclein seeded aggregation in SH-SY5Y cells. Communications Biology, 2021, 4, 613.	2.0	26
5	Editorial: Tau Pathology in Neurological Disorders. Frontiers in Neurology, 2021, 12, 754669.	1.1	2
6	Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates. Science Advances, 2021, 7, eabg4980.	4.7	60
7	Tau aggregation and its relation to selected forms of neuronal cell death. Essays in Biochemistry, 2021, 65, 847-857.	2.1	7
8	The microglial P2Y6 receptor mediates neuronal loss and memory deficits in neurodegeneration. Cell Reports, 2021, 37, 110148.	2.9	31
9	Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate. Neurobiology of Disease, 2020, 138, 104789.	2.1	19
10	Depopulation of dense Î±-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinsonâ€™s disease model. Acta Neuropathologica, 2019, 138, 575-595.	3.9	79
11	Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology. International Journal of Molecular Sciences, 2019, 20, 141.	1.8	52
12	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain, 2018, 141, 521-534.	3.7	114
13	Neurodegeneration and the ordered assembly of Î±-synuclein. Cell and Tissue Research, 2018, 373, 137-148.	1.5	79
14	Living Neurons with Tau Filaments Aberrantly Expose Phosphatidylserine and Are Phagocytosed by Microglia. Cell Reports, 2018, 24, 1939-1948.e4.	2.9	118
15	Propagation of Tau aggregates. Molecular Brain, 2017, 10, 18.	1.3	154
16	Antibody recognizing 4-sulfated chondroitin sulfate proteoglycans restores memory in tauopathy-induced neurodegeneration. Neurobiology of Aging, 2017, 59, 197-209.	1.5	49
17	The Synucleinopathies: Twenty Years On. Journal of Parkinson's Disease, 2017, 7, S51-S69.	1.5	350
18	Atypical, non-standard functions of the microtubule associated Tau protein. Acta Neuropathologica Communications, 2017, 5, 91.	2.4	157

#	Article	IF	Citations
19	Astrocytes in mouse models of tauopathies acquire early deficits and lose neurosupportive functions. Acta Neuropathologica Communications, 2017, 5, 89.	2.4	83
20	Progressive tauopathy in P301S tau transgenic mice is associated with a functional deficit of the olfactory system. European Journal of Neuroscience, 2016, 44, 2396-2403.	1.2	12
21	Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation. Glia, 2016, 64, 457-471.	2.5	16
22	Synaptic failure and Î±â€šsynuclein. Movement Disorders, 2016, 31, 169-177.	2.2	126
23	Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy. Journal of Neuroscience, 2016, 36, 2086-2100.	1.7	56
24	The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice. Frontiers in Neuroscience, 2015, 9, 184.	1.4	34
25	Parkinson's disease as a member of Prion-like disorders. Virus Research, 2015, 207, 38-46.	1.1	30
26	Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients withMAPTmutations. Brain, 2015, 138, 3345-3359.	3.7	116
27	Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure. Neurochemistry International, 2015, 85-86, 14-23.	1.9	30
28	Î±-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. Journal of Cell Science, 2015, 128, 2231-2243.	1.2	99
29	Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology. Experimental Neurology, 2015, 265, 48-58.	2.0	104
30	pFTAA - a high affinity oligothiophene probe that detects filamentous tau in vivo and in cultured neurons. Neural Regeneration Research, 2015, 10, 1746.	1.6	14
31	The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neurons. Acta Neuropathologica, 2014, 127, 283-295.	3.9	29
32	Anti-amyloid Compounds Inhibit Î±-Synuclein Aggregation Induced by Protein Misfolding Cyclic Amplification (PMCA). Journal of Biological Chemistry, 2014, 289, 11897-11905.	1.6	83
33	Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra. Experimental Neurology, 2013, 248, 541-545.	2.0	60
34	100 years of Lewy pathology. Nature Reviews Neurology, 2013, 9, 13-24.	4.9	939
35	Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model. Neurobiology of Aging, 2013, 34, 1355-1368.	1.5	8
36	Tau pathology and neurodegeneration. Lancet Neurology, The, 2013, 12, 609-622.	4.9	893

#	Article	IF	Citations
37	Tau Pathology is PresentIn Vivoand DevelopsIn Vitroin Sensory Neurons from Human P301S Tau Transgenic Mice: A System for Screening Drugs against Tauopathies. Journal of Neuroscience, 2013, 33, 18175-18189.	1.7	36
38	Frontotemporal Dementia: Implications for Understanding Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006254-a006254.	2.9	127
39	Reduced Axonal Transport and Increased Excitotoxic Retinal Ganglion Cell Degeneration in Mice Transgenic for Human Mutant P301S Tau. PLoS ONE, 2012, 7, e34724.	1.1	56
40	Synucleinopathies and Tauopathies. , 2012, , 829-843.		5
41	Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. Movement Disorders, 2012, 27, 312-315.	2.2	56
42	Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: Effects on axonal viability. Neurobiology of Aging, 2011, 32, 419-433.	1.5	108
43	Compound heterozygosity of 2 novel MAPT mutations in frontotemporal dementia. Neurobiology of Aging, 2011, 32, 757.e1-757.e11.	1.5	13
44	Redistribution of DAT/Î±-Synuclein Complexes Visualized by â€œIn Situâ€•Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease. PLoS ONE, 2011, 6, e27959.	1.1	62
45	Pathogenesis of the Tauopathies. Journal of Molecular Neuroscience, 2011, 45, 425-431.	1.1	107
46	Presence of Reactive Microglia and Neuroinflammatory Mediators in a Case of Frontotemporal Dementia with P301S Mutation. Neurodegenerative Diseases, 2011, 8, 221-229.	0.8	74
47	Release of growth factors by neuronal precursor cells as a treatment for diseases with tau pathology. Archives Italiennes De Biologie, 2011, 149, 215-23.	0.1	9
48	Abnormal tau phosphorylation in primary progressive multiple sclerosis. Acta Neuropathologica, 2010, 119, 591-600.	3.9	30
49	Human Stem Cell-Derived Neurons: A System to Study Human Tau Function and Dysfunction. PLoS ONE, 2010, 5, e13947.	1.1	31
50	Cell-Mediated Neuroprotection in a Mouse Model of Human Tauopathy. Journal of Neuroscience, 2010, 30, 9973-9983.	1.7	106
51	Early behavioural markers of disease in P301S tau transgenic mice. Behavioural Brain Research, 2010, 208, 250-257.	1.2	76
52	SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinsonâ€™s disease. Brain, 2010, 133, 2032-2044.	3.7	236
53	Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis. Acta Neuropathologica, 2009, 117, 583-589.	3.9	35
54	Analysis of Tau Phosphorylation and Truncation in a Mouse Model of Human Tauopathy. American Journal of Pathology, 2008, 172, 123-131.	1.9	113

#	Article	IF	Citations
55	Frontotemporal Dementia with Tau Pathology. Neurodegenerative Diseases, 2007, 4, 236-253.	0.8	69
56	Interaction of tau protein with the dynactin complex. EMBO Journal, 2007, 26, 4546-4554.	3.5	171
57	Hereditary Frontotemporal Dementia Caused by Tau Gene Mutations. Brain Pathology, 2007, 17, 63-73.	2.1	182
58	Mutations in the tau gene (MAPT) in FTDP-17: The family with Multiple System Tauopathy with Presenile Dementia (MSTD). Journal of Alzheimer's Disease, 2006, 9, 373-380.	1.2	18
59	A Century of Alzheimer's Disease. Science, 2006, 314, 777-781.	6.0	1,798
60	Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human Â-Synuclein(1-120): Implications for Lewy Body Disorders. Journal of Neuroscience, 2006, 26, 3942-3950.	1.7	302
61	Tau and Î±-Synuclein Inclusions in a Case of Familial Frontotemporal Dementia and Progressive Aphasia. Journal of Neuropathology and Experimental Neurology, 2005, 64, 245-253.	0.9	39
62	Association Between Tau H2 Haplotype and Age at Onset in Frontotemporal Dementia. Archives of Neurology, 2005, 62, 1419.	4.9	40
63	Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nature Genetics, 2005, 37, 806-808.	9.4	752
64	Alpha-synuclein dysfunction in Lewy body diseases. Movement Disorders, 2005, 20, S37-S44.	2.2	76
65	Induction of Inflammatory Mediators and Microglial Activation in Mice Transgenic for Mutant Human P301S Tau Protein. American Journal of Pathology, 2004, 165, 1643-1652.	1.9	180
66	Tau Protein in Familial and Sporadic Diseases. NeuroMolecular Medicine, 2003, 4, 37-48.	1.8	35
67	Ubiquitination of Î±-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function. Journal of Biological Chemistry, 2003, 278, 44405-44411.	1.6	325
68	Tau Protein in Frontotemporal Dementia Linked to Chromosome 3 (FTD-3). Journal of Neuropathology and Experimental Neurology, 2003, 62, 878-882.	0.9	36
69	TAU GENE MUTATIONS IN FRONTOTEMPORAL DEMENTIA AND PARKINSONISM LINKED TO CHROMOSOME 17. , 2003, , .		0
70	The neurobiology of the tauopathies. , 2003, , 245-261.		0
71	Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein. Journal of Neuroscience, 2002, 22, 9340-9351.	1.7	643
72	Proteasomal degradation of tau protein. Journal of Neurochemistry, 2002, 83, 176-185.	2.1	302

#	Article	IF	Citations
73	Molecular Biology of Lewy Body Formation. Advances in Behavioral Biology, 2002, , 483-489.	0.2	0
74	Î±-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Letters, 2001, 509, 22-26.	1.3	326
75	Pick's disease associated with the novelTau gene mutation K369I. Annals of Neurology, 2001, 50, 503-513.	2.8	128
76	From genetics to pathology: tau and aâ€“synuclein assemblies in neurodegenerative diseases. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 213-227.	1.8	58
77	TauGene Mutation K257T Causes a Tauopathy Similar to Pick's Disease. Journal of Neuropathology and Experimental Neurology, 2000, 59, 990-1001.	0.9	145
78	A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). Annals of Neurology, 2000, 47, 422-429.	2.8	109
79	A noveltau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Annals of Neurology, 2000, 48, 939-943.	2.8	136
80	Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimerâ€™s disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1502, 110-121.	1.8	127
81	The Î±â€Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy. Annals of the New York Academy of Sciences, 2000, 920, 16-27.	1.8	437
82	Progress in Hereditary Tauopathies: A Mutation in the Tau Gene (G389R) Causes a Pick Diseaseâ€like Syndrome. Annals of the New York Academy of Sciences, 2000, 920, 52-62.	1.8	30
83	Tau Gene Mutations in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (FTDPâ€17): Their Relevance for Understanding the Neurogenerative Process. Annals of the New York Academy of Sciences, 2000, 920, 74-83.	1.8	54
84	A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). , 2000, 47, 422.		6
85	A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Annals of Neurology, 2000, 48, 939-43.	2.8	40
86	Frontotemporal Dementia and Corticobasal Degeneration in a Family with a P301S Mutation in Tau. Journal of Neuropathology and Experimental Neurology, 1999, 58, 667-677.	0.9	381
87	Tau protein pathology in neurodegenerative diseases. Trends in Neurosciences, 1998, 21, 428-433.	4.2	652
88	Filamentous Î±-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience Letters, 1998, 251, 205-208.	1.0	941
89	Filamentous nerve cell inclusions in neurodegenerative diseases. Current Opinion in Neurobiology, 1998, 8, 619-632.	2.0	247
90	Tau Mutations Cause Frontotemporal Dementias. Neuron, 1998, 21, 955-958.	3.8	294

#	Article	IF	Citations
91	Synthetic filaments assembled from C-terminally truncated Î±-synuclein. FEBS Letters, 1998, 436, 309-312.	1.3	373
92	Nonâ€Alzheimer Degenerative Dementias. Brain Pathology, 1998, 8, 295-297.	2.1	13
93	Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17: A New Group of Tauopathies. Brain Pathology, 1998, 8, 387-402.	2.1	396
94	Î±-Synuclein in Lewy bodies. Nature, 1997, 388, 839-840.	13.7	7,181
95	Assignment of Human Î±-Synuclein (SNCA) and Î²-Synuclein (SNCB) Genes to Chromosomes 4q21 and 5q35. Genomics, 1995, 27, 379-381.	1.3	105
96	Identification of two distinct synucleins from human brain. FEBS Letters, 1994, 345, 27-32.	1.3	922